Phosphoric Acid

Phosphoric Acid

SCHEMBL150929

O=P([O-])([O-])[O-].O=P([O-])([O-])[O-].[H+].[H+].[H+].[Na+].[Na+].[Na+]

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

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

The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.43
SLC34A1 Q06495 1/20 0.42
KDM4E B2RXH2 1/20 0.35
CYP2C19 P33261 1/20 0.35
KMT2A Q03164 1/20 0.35
CA1 P00915 2/20 0.33
CA4 P22748 2/20 0.33
CA5A P35218 2/20 0.33
CA5B Q9Y2D0 2/20 0.33
BLM P54132 1/20 0.32
PMP22 Q01453 1/20 0.32
CYP2C9 P11712 1/20 0.32
TSHR P16473 1/20 0.32
ALOX12 P18054 1/20 0.32
NFKB1 P19838 1/20 0.32
MAPK1 P28482 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phosphoric Acid SCHEMBL49035 1.00
Phosphoric Acid SCHEMBL7525209 1.00 LMNA (0.43) LMNASLC34A1KDM4ECYP2C19KMT2A
Phosphoric Acid SCHEMBL11659 1.00
Phosphoric Acid SCHEMBL18260580 1.00 LMNA (0.43) LMNASLC34A1KDM4ECYP2C19KMT2A
Phosphoric Acid SCHEMBL2902509 1.00 LMNA (0.43) LMNASLC34A1KDM4ECYP2C19KMT2A
Phosphoric Acid SCHEMBL2837841 1.00 LMNA (0.43) LMNASLC34A1KDM4ECYP2C19KMT2A
Phosphoric Acid SCHEMBL7921264 0.94
Phosphoric Acid SCHEMBL19974227 0.94 SLC34A1 (0.50) LMNASLC34A1KDM4ECYP2C19KMT2A
Phosphoric Acid SCHEMBL22263534 0.94 LMNA (0.40) LMNASLC34A1KDM4ECYP2C19KMT2A
Phosphoric Acid SCHEMBL22263543 0.94 LMNA (0.40) LMNASLC34A1KDM4ECYP2C19KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116926971-B Antigen fibrillation composition and application thereof in lyocell fabric 广东德美精细化工集团股份有限公司 2024-07-12 CN claimed
CN-114951252-B Super-capacitor type soil heavy metal ion in-situ removal method and device 长沙稷下科技咨询有限公司 2024-06-18 CN claimed
CN-117090052-A Preparation method of antigen fibrillated lyocell fibers 广东德美精细化工集团股份有限公司 2023-11-21 CN claimed
CN-116926971-A Antigen fibrillation composition and application thereof in lyocell fabric 广东德美精细化工集团股份有限公司 2023-10-24 CN claimed
CN-108586769-A A kind of fluorescence dissaving polymer modified collagen protein material and preparation method thereof 烟台大学 2018-09-28 CN claimed
CN-106546668-A A kind of HPLC methods for separating good fortune department's fluconazole or its pharmaceutical salts about material 陕西合成药业股份有限公司 2017-03-29 CN claimed
EP-0760106-B1 METHOD OF INCREASING THE CONCENTRATION OF RADIATION-ABSORBING AGENTS IN OPTICAL AND OPHTHALMIC LENSES NOVARTIS AG (CH) 1999-07-07 EP claimed
EP-0760106-A1 METHOD OF INCREASING THE CONCENTRATION OF RADIATION-ABSORBING AGENTS IN OPTICAL AND OPHTHALMIC LENSES Novartis AG (CH) 1997-03-05 EP claimed
US-5480927-A Method of increasing the concentration of radiation-absorbing agents in optical and ophthalmic lenses CIBA GEIGY CORPORATION (US) 1996-01-02 US claimed
WO-1995032440-A1 METHOD OF INCREASING THE CONCENTRATION OF RADIATION-ABSORBING AGENTS IN OPTICAL AND OPHTHALMIC LENSES CIBA-GEIGY AG (CH) 1995-11-30 WO claimed
US-20260124128-A1 COMPOSITION COMPRISING LARGE AMOUNT OF POLYOL L'OREAL (FR) 2026-05-07 US disclosed
US-12605324-B2 Composition comprising ingredients for DIC-gel and polyol L'OREAL (FR) 2026-04-21 US disclosed
US-12453691-B2 Composition comprising hyaluronic acid-based polyion complex particle L'OREAL (FR) 2025-10-28 US disclosed
EP-4598499-A1 COSMETIC COMPOSITION FOR A MATTE FOUNDATION L'OREAL (FR) 2025-08-13 EP disclosed
EP-4580586-A1 COSMETIC WATER IN OIL COMPOSITION COMPRISING POLYVINYLPYRROLIDONE AS THICKENER L'OREAL (FR) 2025-07-09 EP disclosed
US-20050187135-A1 Process for producing a refined product of polyoxyproylene fatty acid isopropanolamide surfactant KAWAKEN FINE CHEMICALS CO., LTD. (JP) 2005-08-25 US disclosed
US-20030176311-A1 Purified polyoxypropylene fatty acid isopropanolamide surfactants, production thereof and detergent compositions containing the surfactants KAWAKEN FINE CHEMICALS CO., LTD. (JP) 2003-09-18 US disclosed
EP-1298123-A1 PURIFIED POLYOXYPROPYLENE FATTY ACID ISOPROPANOLAMIDE SURFACTANTS, PRODUCTION THEREOF AND DETERGENT COMPOSITIONS CONTAINING THE SURFACTANTS Kawaken Fine Chemicals Co., Ltd. (JP) 2003-04-02 EP disclosed
US-5480927-A Method of increasing the concentration of radiation-absorbing agents in optical and ophthalmic lenses CIBA GEIGY CORPORATION (US) 1996-01-02 US disclosed
EP-0621284-A1 PEPTIDES CONTAINING RESPECTIVE AMINO ACID SEQUENCES SELECTED FROM AMONG THOSE OF LIPOPROTEIN(a) AND APOLIPOPROTEIN(a), ANTIBODIES RESPECTIVELY RECOGNIZING THESE AMINO ACID SEQUENCES, AND METHOD OF ASSAYING WITH THESE ANTIBODIES SHINO-TEST CORPORATION (JP) 1994-10-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12605324-B2 Composition comprising ingredients for DIC-gel and polyol ALG1, DAD1, DDOST LMNA 981/4885SLC34A1 1663/4885KDM4E 3428/4885
US-20260124128-A1 COMPOSITION COMPRISING LARGE AMOUNT OF POLYOL GK, PRKG2, PRKG1 LMNA 1411/4885SLC34A1 2995/4885KDM4E 3156/4885
US-12453691-B2 Composition comprising hyaluronic acid-based polyion complex particle CD44, PRKCA, H1-0 LMNA 2659/4885SLC34A1 434/4885KDM4E 4101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.